Otsuka to stop development of Alzheimer's disease drug
22/05/2024 13:07
May 22 (Reuters) - Japan's Otsuka Pharmaceutical said on Wednesday it will stop development of its experimental drug to treat patients with agitation associated with Alzheimer's disease. (Reporting by Mariam Sunny in Bengaluru; Editing by Maju Samuel) ((Mariam.ESunny@thomsonreuters.com;))
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug